Evolent Health (NYSE:EVH) Price Target Raised to $7.00

Evolent Health (NYSE:EVH) had its price objective increased by analysts at Oppenheimer from $6.00 to $7.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has an “outperform” rating on the technology company’s stock. Oppenheimer‘s price target points to a potential upside of 51.35% from the stock’s previous close.

A number of other brokerages have also issued reports on EVH. Needham & Company LLC boosted their target price on Evolent Health from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Thursday. Citigroup upgraded Evolent Health from a “neutral” rating to a “buy” rating and decreased their price target for the company from $6.75 to $6.00 in a research report on Monday, August 10th. Truist Financial dropped their price target on Evolent Health from $7.00 to $6.00 and set a “hold” rating on the stock in a research note on Wednesday, August 12th. TD Cowen boosted their price objective on Evolent Health from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Monday, August 17th. Finally, Canaccord Genuity Group cut their price objective on Evolent Health from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Eleven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $6.11.

Evolent Health Price Performance

Evolent Health stock traded up $0.09 during midday trading on Friday, hitting $4.62. The company’s stock had a trading volume of 820,560 shares, compared to its average volume of 2,833,896. The company has a quick ratio of 1.24, a current ratio of 1.24 and a debt-to-equity ratio of 2.52. The stock’s 50-day moving average price is $4.17 and its 200-day moving average price is $3.88. Evolent Health has a 12 month low of $2.10 and a 12 month high of $6.28. The company has a market capitalization of $522.90 million, a PE ratio of -1.01 and a beta of 1.03.

Evolent Health (NYSE:EVH) last posted its quarterly earnings results on Thursday, November 5th. The technology company reported $0.06 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.06. The company had revenue of $725.37 million for the quarter, compared to analysts’ expectations of $727.06 million. Evolent Health had a negative return on equity of 4.27% and a negative net margin of 24.08%. The firm’s revenue was up 51.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.05 earnings per share. Analysts anticipate that Evolent Health will post -0.25 earnings per share for the current fiscal year.

Insider Transactions at Evolent Health

In other Evolent Health news, President Daniel Mccarthy sold 65,892 shares of the business’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $5.00, for a total transaction of $329,460.00. Following the sale, the president directly owned 655,133 shares of the company’s stock, valued at $3,275,665. The trade was a 9.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.48% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Public Employees Retirement System of Ohio purchased a new stake in Evolent Health in the 2nd quarter worth about $760,000. First Trust Advisors LP purchased a new position in Evolent Health during the 1st quarter valued at about $488,000. WINTON GROUP Ltd grew its stake in Evolent Health by 29.6% during the 2nd quarter. WINTON GROUP Ltd now owns 26,700 shares of the technology company’s stock valued at $145,000 after acquiring an additional 6,100 shares in the last quarter. Corient Private Wealth LP increased its holdings in shares of Evolent Health by 447.4% in the 2nd quarter. Corient Private Wealth LP now owns 81,594 shares of the technology company’s stock valued at $442,000 after purchasing an additional 66,687 shares during the period. Finally, HB Wealth Management LLC increased its holdings in shares of Evolent Health by 6.8% in the 2nd quarter. HB Wealth Management LLC now owns 35,842 shares of the technology company’s stock valued at $194,000 after purchasing an additional 2,282 shares during the period.

Evolent Health News Summary

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Needham raised its price target to $6 from $5 and maintained a Buy rating, implying about 31% upside from the cited $4.58 share price. Needham analyst rating
• Positive Sentiment: Management’s FY 2026 revenue outlook is $2.6 billion–$2.7 billion. The upper end is above the roughly $2.6 billion analyst consensus, though the range’s midpoint is close to expectations.
• Positive Sentiment: Q3 revenue grew 51.3% year over year to $725.37 million, and EPS of $0.06 matched consensus and exceeded the year-ago $0.05. The company also said customers are renewing and, in many cases, expanding their work with Evolent. Q3 results
• Negative Sentiment: Revenue came in slightly below analysts’ $727.06 million estimate. The reported negative net margin and negative return on equity also underline ongoing profitability challenges.

About Evolent Health

Evolent Health, Inc (NYSE: EVH) is a healthcare services and technology company that helps health plans and healthcare providers transition to value-based care. Its platform is designed to support the management of clinical programs, improve patient outcomes and coordinate care while helping customers manage healthcare costs.

The company provides specialty and total-cost-of-care solutions across areas such as cardiology, oncology, musculoskeletal care, radiology and other complex conditions.